

# Resource Summary Report

Generated by [dkNET](#) on Aug 1, 2026

## CD3

RRID:AB\_2744392

Type: Antibody

---

### Proper Citation

BD Biosciences Cat# 563724, RRID:AB\_2744392

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2744392](http://antibodyregistry.org/AB_2744392)

**Proper Citation:** BD Biosciences Cat# 563724, RRID:AB\_2744392

**Target Antigen:** CD3

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: Flow cytometry

**Antibody Name:** CD3

**Description:** This monoclonal targets CD3

**Target Organism:** human

**Clone ID:** UCHT1

**Antibody ID:** AB\_2744392

**Vendor:** BD Biosciences

**Catalog Number:** 563724

**Alternative Catalog Numbers:** 563725

**Record Creation Time:** 20250820T054617+0000

**Record Last Update:** 20250820T222512+0000

---

### Ratings and Alerts

No rating or validation information has been found for CD3.

No alerts have been found for CD3.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 16 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

von Locquenghien M, et al. (2025) Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy. *Cell*, 188(25), 7099.

Chauveau C, et al. (2025) MEK inhibition prevents human skin graft rejection by promoting CD8+TCF1+ over CD8 effector T cells. *iScience*, 28(9), 113310.

Camard L, et al. (2025) IL-23 tunes inflammatory functions of human mucosal-associated invariant T cells. *iScience*, 28(2), 111898.

Das Adhikari U, et al. (2025) Immunometabolic defects of CD8+ T cells disrupt gut barrier integrity in people with HIV. *Cell*.

Henrich TJ, et al. (2024) Sirolimus reduces T cell cycling, immune checkpoint marker expression, and HIV-1 DNA in people with HIV. *Cell reports. Medicine*, 5(10), 101745.

Diepstraten ST, et al. (2024) Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. *Cancer cell*, 42(5), 850.

Chiffelle J, et al. (2024) Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma. *Immunity*, 57(10), 2466.

Lameris R, et al. (2023) A bispecific T cell engager recruits both type 1 NKT and V $\alpha$ 9V $\beta$ 2-T cells for the treatment of CD1d-expressing hematological malignancies. *Cell reports. Medicine*, 4(3), 100961.

Trinh T, et al. (2023) CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies. *iScience*, 26(4), 106443.

Rasmussen TA, et al. (2022) Memory CD4+ T cells that co-express PD1 and CTLA4 have reduced response to activating stimuli facilitating HIV latency. *Cell reports. Medicine*, 3(10), 100766.

Cheng J, et al. (2022) IL-27 induces IFN/STAT1-dependent genes and enhances function of TIGIT+ HIVGag-specific T cells. *iScience*, 25(1), 103588.

Zaitsev A, et al. (2022) Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. *Cancer cell*, 40(8), 879.

Lulu AM, et al. (2021) Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients. *Cancer immunology research*, 9(11), 1327.

Rodda LB, et al. (2021) Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. *Cell*, 184(1), 169.

Argüello RJ, et al. (2020) SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell Resolution. *Cell metabolism*, 32(6), 1063.

Gannon PO, et al. (2020) Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment. *Cytotherapy*, 22(12), 780.